SPECIAL-CAPNOSTREAM20-Two  Parameter  Monitor With  A2  Software 

CONFIDENTIAL

monitoring  of carbon  dioxide  concentration  of the
expired  and  inspired  breath  and  respiration  rate,
and  for the  continuous  non-invasive  monitoring  of
functional  oxygen  saturation  of arterial
hemoglobin  (Sp0 2 and  pulse  rate).  It is intended
for  use with  neonatal,  pediatric  and  adult  patients
in hospitals,  hospital  type  facilities,  intra  hospital
transport  and  home  environments.

Target 
population 

Design 

Where  Used 

It is intended  for  use  with  neonatal, 
pediatric, and  adult  patients. 

It is intended  for  use with  neonatal,  pediatric,  and
adult patients.

Identical  to  MiniMediCO 2 module  in  See  K060065
K060065  with  the exception  of
software  version  change  from  2.20
to 2.31

It is to  be  used  by  physicians, 
nurses  and  other trained  health 
care  providers  in critical  care 
patient settings,  such  as 
anesthesiology,  intensive  care 
medicine,  neonatal  Intensive  care
and  other  health  care  areas

It is to  be used  by  physicians,  nurses and  other
trained  health  care  providers  in critical  care
patient  settings,  such  as anesthesiology,
intensive  care  medicine,  neonatal  Intensive  care
and  other  health  care  areas

Performance 
Standards 

IS021647 
ISO  9919 

IS021647
ISO  9919

Safety 
Standards

IEC/EN60601-1 

IEC/EN60601-1

IEC/EN60601-1-2(2001) 

IEC/EN60601-1-2(2001)

IEC60601-1-8 

UL60601-1 

ISO  14971 

IEC60601-1-8

UL60601-1

ISO  14971

Biocompatibility 

Sterility 

There  are  no  issues  of 
biocompatibility  for this device  and 
no biocompatibility  testing  was
done.

This  device  does  not  require 
sterilization  and  is shipped  marked 
non-sterile.

There  are  no  issues of  biocompatibility  for this
device  and  no  biocompatibility  testing  was  done.

This  device  does  not  require  sterilization  and  is
shipped  marked  non-sterile.

CONCLUSION

Capnostream 20 with  adaptive  averaging  software  does  not  raise  any  new  potential  safety

risks  and  is  equivalent  in performance  to the  existing  legally  marketed  device.  Therefore,

the  device  is  substantially  equivalent  to the  predicate  device  with  respect  to  safety

effectiveness,  and  intended  use.

Oridion  Medical  1987  Ltd. 

18

